CRISPR THERAPTC (CRSP) vs. Editas Medicine (NASDAQ:EDIT) Critical Review – The Ledger Gazette
|
CRISPR THERAPTC (CRSP) vs. Editas Medicine (NASDAQ:EDIT) Critical Review
The Ledger Gazette CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular … |
